


Amendments to the Claims

1. (currently amended) A compound of Formula (I)



or pharmaceutically acceptable salt or solvate thereof

wherein

A^1 and A^2 are each independently C_{1-4} alkylene or a bond;

A^3 is a bond, C_{1-4} alkylene or C_{1-4} alkylidene;

A^4 is C_{1-4} alkylene or a bond and is attached to X , X^1 or X^2 ;

X , X^1 , X^2 and X^3 are independently C or CH;

J is C_{1-4} alkyl;

p is 0 or 1;

R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O- C_{1-4} alkyl or C_{1-4} alkyl-N(H)C(O)O-;

said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy, indolyl or halo;

wherein said indolyl is optionally substituted by halo or cyano;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolynyl, imidazolidinyl, pyrazolyl, pyrazolynyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolynyl, quinolynyl, dihydroquinolynyl, tetrahydroquinolynyl, isoquinolynyl, dihydroisoquinolynyl and tetrahydroisoquinolynyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano;

or wherein -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form ~~pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolynyl, imidazolidinyl, pyrazolyl, pyrazolynyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolynyl, isoindolynyl, quinolynyl, dihydroquinolynyl, tetrahydroquinolynyl, isoquinolynyl, dihydroisoquinolynyl or tetrahydroisoquinolynyl~~ and are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy, cyano or benzyl;

R³ is H or C₁₋₄alkyl;

m is 0 or 1;

R⁴ and R⁵ are independently hydrogen, cyano, halo, nitro, C₁₋₃alkyl or C₁₋₃perfluoroalkyl;

wherein said R⁴ or R⁵ may be independently attached to G¹, X, X¹, X² or X³;

n is 0 or 1;

G is N, O or S;

G¹ is N, C or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

both R^4 and R^5 are not attached to the same of said G^1 , X , X^1 , X^2 or X^3 ;

if G is O or S , then m is 0 ;

if G is N , then m is 1 ;

if R_1 is C_{3-6} cycloalkyl, phenyl or O -phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy, indolyl or halo; wherein said indolyl is optionally substituted by halo or cyano, then R_2 is H or C_{1-3} alkyl;

if R_2 is C_{3-6} cycloalkyl, phenyl or O -phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy, indolyl or halo; wherein said indolyl is optionally substituted by halo or cyano, then R_1 is H or C_{1-3} alkyl;

if $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano or benzyl, then p is 0 ;

if R^1 is $-N(H)C(O)OC_{1-4}$ alkyl, C_{1-4} alkyl- $N(H)C(O)O-$ or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^1 , then A^1 is C_{2-4} alkylene;

if R^2 is $-N(H)C(O)OC_{1-4}$ alkyl, C_{1-4} alkyl- $N(H)C(O)O-$ or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A^2 , then A^2 is C_{2-4} alkylene;

if R^1 is $N(H)C(O)O-C_{1-4}$ alkyl, C_{1-4} alkyl- $N(H)C(O)O-$ or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny,

imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R² is H or C₁₋₃alkyl;

if R² is -N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R¹ is H or C₁₋₃alkyl;

if R⁴ or R⁵ are attached to G¹, then G¹ is C;

if A⁴, R⁴ or R⁵ are attached to X, then X is C;

if A⁴, R⁴ or R⁵ are attached to X¹, then X¹ is C;

if A⁴, R⁴ or R⁵ are attached to X², then X² is C;

if R⁴ or R⁵ are attached to X³, then X³ is C.

2. (original) A compound according to claim 1 wherein p is 0.
3. (original) A compound according to claim 1 wherein G is N and G¹ is CH.
4. (original) A compound according to claim 1 wherein G is S and G¹ is CH.
5. (original) A compound according to claim 1 wherein G is N and G¹ is N.
6. (original) A compound according to claim 1 wherein G is S and G¹ is N.
7. (original) A compound according to claim 1 wherein G is O and G¹ is N.

8. (original) A compound according to claim 1 wherein R^1 is methyl and R^2 is methyl.
9. (original) A compound according to claim 1 wherein R^1 is H and R^2 is C_{3-6} cycloalkyl wherein said C_{3-6} cycloalkyl is substituted with indolyl and wherein said indolyl is optionally substituted by halo or cyano.
10. (original) A compound according to claim 1 wherein A^1 is a bond, R^1 is methyl, A^2 is a bond and R^2 is methyl.
11. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3} alkyl, C_{3-6} cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O- C_{1-4} alkyl or C_{1-4} alkyl-N(H)C(O)O-; said C_{3-6} cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo.
12. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H, C_{1-3} alkyl, phenyl, said phenyl being independently and optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy or halo.
13. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H or unsubstituted C_{1-3} alkyl or phenyl.
14. (original) A compound according to claim 1 wherein R^1 and R^2 are independently H or unsubstituted C_{1-3} alkyl or phenyl and A^1 and A^2 are independently C_{1-4} alkylene.
15. (original) A compound according to claim 1 wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolyl, pyrrolinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, C_{1-4} alkyl, C_{1-4} alkoxy, cyano or benzyl.
16. (original) A compound according to claim 1 wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form unsubstituted pyrrolyl, pyrrolinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholino, indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl or tetrahydroisoquinolinyl.
17. (original) A compound according to claim 1 wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form unsubstituted pyrrolidinyl, piperidinyl, morpholino or isoindolinyl.

18. (original) A compound according to claim 1 wherein R^3 is H and m is 1.
19. (original) A compound according to claim 1 wherein n is 0.
20. (original) A compound according to claim 1 wherein R^4 and R^5 are halo.
21. (original) A compound according to claim 1 wherein R^4 is C_{1-3} alkyl and is attached to G^1 .
22. (original) A compound according to claim 1 wherein R^4 is C_{1-3} perfluoroalkyl and is attached to G^1 .
23. (original) A compound according to claim 1 wherein R^4 is hydrogen.
24. (original) A compound according to claim 1 wherein R^4 is fluoro.
25. (original) A compound according to claim 1 wherein R^4 is cyano.
26. (original) A compound according to claim 1 wherein R^4 is cyano or fluoro.
27. (original) A compound according to claim 1 wherein R^4 and R^5 are each fluoro.
28. (original) A compound according to claim 1 wherein the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.
29. (original) A compound according to claim 1 wherein the hydrogen atom attached to D is in the *cis* configuration to the hydrogen atom attached to E.
30. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of S.
31. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of R.
32. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of R; E in relation to the four moieties to which it is attached has an absolute configuration of S.
33. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of R; E in relation to the four moieties to which it is attached has an absolute configuration of R.
34. (original) A compound according to claim 1 wherein A^3 is a bond.
35. (original) A compound according to claim 1 wherein A^3 is C_{1-4} alkylene.
36. (original) A compound according to claim 1 wherein A^3 is C_{1-4} alkylidene.
37. (original) A compound according to claim 1 wherein A^3 is methylene.

38. (original) A compound according to claim 1 wherein A⁴ is a bond.

39. (original) A compound according to claim 1 wherein A⁴ is methylene.

40. (original) A compound according to claim 1 wherein A⁴ is attached X¹.

41. (original) A compound according to claim 1 wherein A⁴ is attached X.

42. (original) A compound according to claim 1 wherein R⁴ is attached X.

43. (currently amended) A compound according to claim 1 wherein

A¹ and A² are each independently C₁₋₄alkylene or a bond;

A³ is a bond;

A⁴ is a bond and is attached to X¹;

X and X¹ are each C;

X² and X³ are each CH;

p is 0;

R¹ and R² are independently H, C₁₋₃alkyl, C₃₋₆cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-C₁₋₄alkyl or C₁₋₄alkyl-N(H)C(O)O-;

said C₃₋₆cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with C₁₋₄alkyl, C₁₋₃alkoxy or halo;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano;

or wherein -A¹-R¹ and -A²-R² together with the nitrogen to which they are attached form ~~pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, indolyl,~~

~~isoindolyl, indolyl, isoindolyl, quinolyl, dihydroquinolyl, tetrahydroquinolyl, isoquinolyl, dihydroisoquinolyl or tetrahydroisoquinolyl and are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy, cyano or benzyl;~~

R³ is H;

m is 1;

R⁴ is hydrogen, cyano, halo, nitro, C₁₋₃alkyl or C₁₋₃perfluoroalkyl and is attached to X;

n is 0;

G is N;

G¹ is CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

if R¹ is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A¹, then A¹ is C₂₋₄alkylene;

if R² is -N(H)C(O)OC₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to A², then A² is C₂₋₄alkylene;

if R¹ is N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolyl, imidazolidinyl, pyrazolyl, pyrazolyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolyl, quinolyl, dihydroquinolyl, tetrahydroquinolyl, isoquinolyl, dihydroisoquinolyl and tetrahydroisoquinolyl, wherein said heterocyclic moieties are

optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R² is H or C₁₋₃alkyl; and

if R² is -N(H)C(O)O-C₁₋₄alkyl, C₁₋₄alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, C₁₋₄alkyl, C₁₋₄alkoxy or cyano, then R¹ is H or C₁₋₃alkyl.

44. (original) A pharmaceutically acceptable formulation comprising a compound according to claim 1.
45. (currently amended) A method of treating depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, ~~post-traumatic stress disorder, substance abuse disorders and~~ sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
46. (original) A method of treating sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
47. (original) A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.
48. (original) A compound or pharmaceutically acceptable salt or solvate thereof selected from the group consisting of
 - 3-(3-methylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-(3-ethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
 - 3-(3-dimethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;

3-[3-(ethyl-methyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-(3-diethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-pyrrolidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-[3-(1,3-dihydro-isoindol-2-yl)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-[3-(3,4-dihydro-1*H*-isoquinolin-2-yl)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-(3-penethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-[3-(methyl-phenethyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-(3-morpholin-4-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-[3-(benzyl-methyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
3-(3-benzylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-piperidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-dipropylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-propylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-methylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-ethylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
3-(3-benzylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-phenethylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-dimethylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
3-[3-(ethyl-methyl-amino)-cyclopentyl]-1-methyl-1*H*-indole-5-carbonitrile;
3-(3-diethylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-pyrrolidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-piperidin-1-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-morpholin-4-yl-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-[3-(benzyl-methyl-amino)-cyclopentyl]-1-methyl-1*H*-indole-5-carbonitrile;
1-methyl-3-[3-(methyl-phenethyl-amino)-cyclopentyl]-1*H*-indole-5-carbonitrile;
1-methyl-3-(3-propylamino-cyclopentyl)-1*H*-indole-5-carbonitrile;
3-(3-dipropylamino-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;
3-[3-(benzyl-methyl-amino)-cyclopentyl]-1-ethyl-1*H*-indole-5-carbonitrile;
3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;
3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
ethyl-[3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl]-methyl-amine;
diethyl-[3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl]-amine;
5-fluoro-3-(3-pyrrolidin-1-yl-cyclopentyl)-1*H*-indole;
3-(4-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(4-bromo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(5-dihloro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(5-bromo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(5-iodo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(6-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(6-chloro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(6-bromo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(7-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(7-chloro-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
3-(7-bromo-1*H*-indol-3-yl)-cyclopentyl-dimethyl-amine;
(1*S*,3*R*)-3-(3-dimethylaminocyclopentyl)-1*H*-indole-5-carbonitrile;
(1*S*,3*S*)-3-(3-dimethylaminocyclopentyl)-1*H*-indole-5-carbonitrile;

(1*R*,3*S*)-3-(3-dimethylaminocyclopentyl)-1*H*-indole-5-carbonitrile;
 (1*R*,3*R*)-3-(3-dimethylaminocyclopentyl)-1*H*-indole-5-carbonitrile;
 (1*S*,3*S*)-3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethylamine;
 (1*R*,3*S*)-3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethylamine;
 (1*R*,3*R*)-3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethylamine;
 (1*S*,3*R*)-3-(5-fluoro-1*H*-indol-3-yl)-cyclopentyl-dimethylamine;
 (1*S*,3*R*)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;
 (1*S*,3*S*)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;
 (1*R*,3*S*)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;
 (1*R*,3*R*)-3-(3-dimethylamino-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;
 (1*S*)-3-(3-amino-cyclopentyl)-1*H*-indole-5-carbonitrile; and
 (3*S*,3'*S*)-bis-(3-(5-cyano-1*H*-indol-3-yl)cyclopentyl)amine.